- Home
- / Acerus Pharmaceuticals
Acerus Pharmaceuticals
Total Funding
$18 M
Revenue
($4.1 M)
FY, 2021
Acerus Pharmaceuticals Summary
Company Summary
- Overview
- Acerus Pharmaceuticals (formerly known as Trimel Pharmaceuticals) is a pharmaceutical company focused on the development and commercialization of men's and women's health products. It offers Natesto (nasal testosterone replacement therapy), and Estrace (estradiol therapy). The company aims to create products based on the nasal delivery platform.
- Type
- Private
- Status
- Active
- Founded
- 2008
- HQ
- Mississauga, CA | view all locations
- Cybersecurity rating
Table of Contents
Key People
Edward Gudaitis, President and Chief Executive Officer
Robert Motz, Chief Financial Officer
Philippe Savard, Vice President, General Counsel and Corporate Secretary
LocationsView all
2 locations detected
Mississauga, ON HQ
Canada
2486 Dunwin Dr
Mississauga, ON
Canada
7025 Langer Dr #205
Acerus Pharmaceuticals Financials
Summary Financials
- Revenue (Q3, 2022)
- $770.0K
- Gross profit (Q3, 2022)
- $625.0K
- Net income (Q3, 2022)
- ($4.2M)
- Cash (Q3, 2022)
- $3.0M
- EBIT (Q3, 2022)
- ($2.7M)